Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Yanlong Liu

Fei Liu

Xiquan Zhang

Shanchun Wang

Hongjiang Xu

Hongmei Gu

Weiwei Feng

Huihui Zhang

Bin Wang

Jinan Wang

Jianqing Zhang

Xujing Tang

Ling Yang

Rui Zhao

Hongjian Wang

Wei Shi

Yizhong Zhu

Song Tang

Xinlu Li

Ming Zhang

Wenjun Geng

Hongying Zhang

Zhongyuan Hu

Shanliang Zhu

Yiyan Yao

Yang Li

Limin Liu

Wenyuan Qian

Yahui Guo

Lei Xing

Quandeng Nie

Yubing Wang

Disclosed is a trifluoromethyl-substituted sulfonamide BCL-2-selective inhibitor, in particular disclosed are a compound of formula I, a stereoisomer or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition thereof. Also disclosed are the uses of said compound and of a pharmaceutical composition comprising same for treating anti-apoptotic BCL-2-related diseases, such as cancer.

Trifluoromethyl-substituted sulfonamide as BCL-2-selective inhibitor

The present application relates to the field of medicine, and relates to crystals of quinoline derivatives, and in particular, to crystals of a quinoline derivative anhydride and a solvate, as well as a method for preparing the crystals, pharmaceutical compositions containing the crystals, and a use thereof in the field of medicine. The present application further provides a preparation method therefor, which has a high yield, has mild crystallization conditions, is suitable for industrial production, and may better meet the needs of the pharmaceutical industry.

Crystals of quinolone derivatives

Disclosed is a methyl- and trifluoromethyl-containing disubstituted sulfonamide selective BCL-2 inhibitor; specifically disclosed are a compound of formula I, a stereoisomer or pharmaceutically acceptable salt of same, a preparation method therefor, and a pharmaceutical composition comprising the compound. Also disclosed are uses of the compound and of the pharmaceutical composition comprising the compound in treating anti-apoptotic protein BCL-2-related diseases such as cancer.

Methyl- and trifluoromethyl-containing disubstituted sulfonamide selective BCL-2 inhibitor

Provided is a salt of an Syk inhibitor and a crystalline form thereof, and more specifically, provided are 5-fluoro-1-methyl-3-((5-(4-(oxetan-3-yl)piperazine-1)-yl)pyridin-2-yl)amino)-6-(1H-pyrazol-3-yl)quinoline-2(1H)-ketamine hydrochloride, a crystalline form thereof, a preparation method therefor, a pharmaceutical composition thereof and a use thereof. The hydrochloride of the compound represented by formula I and the crystalline form thereof have good salt-forming properties, high stability and low hygroscopicity, have advantages in terms of physical properties, safety and metabolic stability, and have value in prepared medicines.

Salt of Syk inhibitor and crystalline form thereof

Lamivudine oxalate, preparation method and crystalline forms thereof are disclosed. A preparation method of Lamivudine is also disclosed.

Lamivudine oxalate and preparation method thereof

Growing community of inventors

Jiangsu, China

Yanlong Liu